Both lovastatin [27] and atorvastatin [28] overcame gefitinib resistance in NSCLC cells with K-Ras mutations through down-regulation of RAS protein, which leads to inhibition of both the RAF/ERK and AKT pathways. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.